Lisdexamfetamine
Trials 42 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07314333 | Feb → Mar 2026 | attention deficit-hyperactivity disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07098585 | May → Jun 2025 | attention deficit-hyperactivity disorder | Humanis | Completed | No outcome recorded |
| Phase 1 | NCT02668926 | May → Jun 2016 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01457339 | Oct 2011 → Jan 2012 | schizophrenia | Shire | Completed | No outcome recorded |
| Phase 1 | NCT01490216 | Jul 2011 → Jan 2013 | cocaine dependence | University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT01235338 | Oct → Dec 2010 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT00776555 | Nov 2008 → Mar 2009 | — | Shire | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01486810 | Dec 2011 → Dec 2013 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00573859 | Sep 2006 → Jun 2010 | attention deficit-hyperactivity disorder | University of California, Irvine | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT06788587 | Jul 2025 → Aug 2027 expected | methamphetamine dependence, substance abuse | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Phase 2 | NCT02635035 | Nov 2015 → Jan 2019 | attention deficit-hyperactivity disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT02659488 | Sep 2015 → Sep 2017 | binge eating disorder | Lindner Center of HOPE | Unknown | No outcome recorded |
| Phase 2 | NCT01714310 | Jan 2013 → Jun 2016 | mood disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT01291173 | May 2011 → Jan 2012 | binge eating disorder | Shire | Completed | No outcome recorded |
| Phase 2 | NCT01615887 | Nov 2009 → Aug 2011 | multiple sclerosis | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 2 | NCT00922272 | Sep 2009 → Jan 2011 | schizophrenia | Shire | Completed | No outcome recorded |
| Phase 2 | NCT00905424 | Jul 2009 → Aug 2010 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04599504 | Jan 2022 → May 2027 expected | eating disorder, obesity disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT01718483 | Nov 2012 → Sep 2013 | binge eating disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01718509 | Nov 2012 → Sep 2013 | binge eating disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01436149 | Oct 2011 → Dec 2013 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01436162 | Oct 2011 → Dec 2013 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01106430 | Jun 2010 → Jul 2012 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00763971 | Nov 2008 → Mar 2011 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00764868 | Nov 2008 → Apr 2010 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00337285 | Jul 2006 → Nov 2007 | attention deficit-hyperactivity disorder | New River Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00334880 | May → Nov 2006 | attention deficit-hyperactivity disorder | New River Pharmaceuticals | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT03337646 | Sep 2018 → Mar 2023 | attention deficit-hyperactivity disorder, autism spectrum disorder | JPM van Stralen Medicine Professional | Completed | No outcome recorded |
| Phase 4 | NCT03187353 | Sep 2017 → Apr 2022 | cognitive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT03070509 | May 2017 → Jul 2019 | — | North Dakota State University | Unknown | No outcome recorded |
| Phase 4 | NCT02170298 | Feb 2014 → Jun 2015 | attention deficit-hyperactivity disorder | University of California, Davis | Terminated | No outcome recorded |
| Phase 4 | NCT01924429 | Mar → Dec 2013 | attention deficit-hyperactivity disorder | Jeffrey Newcorn | Completed | No outcome recorded |
| Phase 4 | NCT01324024 | May 2011 → Apr 2014 | cognitive disorder, premature menopause | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01127607 | Nov 2010 → Jul 2012 | attention deficit-hyperactivity disorder | Florida International University | Completed | No outcome recorded |
| Phase 4 | NCT01070394 | Feb 2010 → Jul 2012 | attention deficit-hyperactivity disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT01342445 | Sep 2009 → Dec 2010 | attention deficit-hyperactivity disorder | University of Rhode Island | Completed | No outcome recorded |
| Phase 4 | NCT00753012 | Apr 2008 → Mar 2011 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00500071 | Jun 2007 → Jan 2008 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT03333668 | Oct 2018 → Dec 2022 | attention deficit-hyperactivity disorder | King's College London | Unknown | No outcome recorded |
| — | NCT02259517 | Sep 2014 → Nov 2021 | attention deficit-hyperactivity disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| — | NCT01415440 | Aug 2011 → Jun 2018 | attention deficit-hyperactivity disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT00736255 | Dec 2007 → Jul 2011 | attention deficit-hyperactivity disorder, nicotine dependence | Duke University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02144415 Comparator | May → Jul 2014 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02034201 Comparator | Feb 2014 → May 2016 | methamphetamine dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05957055 Comparator | Feb 2024 → Dec 2027 expected | attention deficit-hyperactivity disorder, type 1 diabetes mellitus | Medical University of Lodz | Recruiting | No outcome recorded |
| Phase 2 | NCT05854667 Comparator | Dec 2023 → Dec 2027 expected | methamphetamine dependence, substance abuse | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Phase 2 | NCT00958282 Comparator | Jul 2009 → Jan 2013 | cocaine dependence | University of Minnesota | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT03924193 Comparator | Mar 2019 → Sep 2023 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT02555150 Comparator | Sep 2015 → Jan 2017 | attention deficit-hyperactivity disorder | Rhodes Pharmaceuticals, L.P. | Completed | No outcome recorded |
| Phase 3 | NCT01131559 Comparator | Jan 2010 → Feb 2014 | bipolar disorder, depressive disorder | Lindner Center of HOPE | Terminated | No outcome recorded |
| Phase 3 | NCT01090713 Comparator | Jan 2010 → Oct 2012 | binge eating disorder | Lindner Center of HOPE | Completed | No outcome recorded |
| Phase 3 | NCT01093963 Comparator | Jan 2010 → Feb 2014 | bipolar depression | Lindner Center of HOPE | Terminated | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT02712996 Comparator | Feb 2017 → Jul 2019 | attention deficit-hyperactivity disorder, traumatic brain injury | Vanderbilt University | Completed | No outcome recorded |
| Phase 4 | NCT01977625 Comparator | Dec 2011 → Apr 2014 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01051440 Comparator | Feb 2010 → Jun 2011 | bipolar depression | Steward St. Elizabeth's Medical Center of Boston, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT01017263 Comparator | Dec 2009 → Aug 2012 | attention deficit-hyperactivity disorder, glucose intolerance, obesity disorder | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT00889915 Comparator | Apr → Dec 2009 | attention deficit-hyperactivity disorder | Duke University | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT05551689 Background | May 2021 → Sep 2022 | attention deficit-hyperactivity disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| — | NCT01986764 Comparator | Jul 2013 | — | University of Pennsylvania | Withdrawn | No outcome recorded |
| — | NCT01986777 Comparator | Jul → Dec 2013 | cognitive impairment with or without cerebellar ataxia | University of Pennsylvania | Withdrawn | No outcome recorded |
| — | NCT00807222 Comparator | Apr → Aug 2008 | attention deficit-hyperactivity disorder | Clinical Study Centers, LLC | Completed | No outcome recorded |
Press releases naming this drug 16 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-04-18 | Takeda | Vyvanse® (lisdexamfetamine dimesylate) CII Available in a New Chewable Tablet Formulation takeda.com ↗ |
| 2016-10-17 | Takeda | Shire Announces Update to Vyvanse® (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder takeda.com ↗ |
| 2016-04-14 | Takeda | Shire Submits NDA to FDA for New Formulation of Vyvanse® (lisdexamfetamine dimesylate) CII as Chewable Tablets takeda.com ↗ |
| 2015-09-24 | Takeda | Appeals Court Affirms Shire’s Vyvanse® (lisdexamfetamine dimesylate) Patents Are Valid Until 2023 takeda.com ↗ |
| 2015-07-22 | Takeda | Vyvanse® (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Moderate to Severe Binge Eating Disorder takeda.com ↗ |
| 2015-03-23 | Takeda | Vyvanse Capsules as a Titration Dose takeda.com ↗ |
| 2015-01-30 | Takeda | Vyvanse® (Lisdexamfetamine Dimesylate) Capsules (CII) Becomes First And Only Treatment Approved By The FDA For Adults With Moderate To Severe Binge Eating Disorder takeda.com ↗ |
| 2015-01-22 | Takeda | Positive Response From European Decentralised Procedure For Elvanse Adult® In Adults With ADHD takeda.com ↗ |
| 2014-09-15 | Takeda | Shire Announces FDA Acceptance For Filing With Priority Review Of Supplemental New Drug Application (Snda) For Vyvanse® (Lisdexamfetamine Dimesylate) Capsules (CII) For Adults With Binge Eating Disorder takeda.com ↗ |
| 2014-07-17 | Takeda | Top-Line Results From Two Head-To-Head Studies Comparing Vyvanse® (Lisdexamfetamine Dimesylate), CII, With Concerta® (Methylphenidate Hcl), CII, In Adolescents With ADHD takeda.com ↗ |
| 2014-06-25 | Takeda | Vyvanse Patents Found To Be Infringed And Valid By U.S. District Court takeda.com ↗ |
| 2014-06-12 | Takeda | Shire Agrees To FDA Request To Conduct Clinical Trials Investigating The Potential Use Of Vyvanse® (Lisdexamfetamine Dimesylate) In Preschool-Age Children With ADHD takeda.com ↗ |
| 2014-02-06 | Takeda | Shire Reports Top-Line Results From Two Phase 3 Studies For Vyvanse® (Lisdexamfetamine Dimesylate) Capsules (CII) As An Adjunctive Treatment For Adults With Major Depressive Disorder takeda.com ↗ |
| 2013-11-05 | Takeda | Positive Top-Line Results Shown For Vyvanse(R) (Lisdexamfetamine Dimesylate) Capsules (CII) In Adults With Binge Eating Disorder takeda.com ↗ |
| 2013-05-01 | Takeda | Vyvanse® (Lisdexamfetamine Dimesylate) Capsules, (CII) Now Approved In The US For Maintenance Treatment In Children And Adolescents With ADHD takeda.com ↗ |
| 2013-02-12 | Takeda | Elvanse ® (Lisdexamfetamine Dimesylate) Receives UK Marketing Authorisation, Providing A New Option For The Treatment Of ADHD In Children And Adolescents In The UK takeda.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 74 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lisdexamfetamine | “OBJECTIVE: To evaluate the efficacy and safety of 30, 50, and 70 mg/day lisdexamfetamine dimesylate compared with placebo in adults with attention-deficit/hyperactivity disorder (ADHD).” PMID 19012818 ↗ Sep 200858“BACKGROUND: Lisdexamfetamine dimesylate (LDX), a prodrug consisting of d-amphetamine and l-lysine, is being studied in clinical trials of major depressive disorder.” PMID 23512639 ↗ Apr 2013 “Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.” PMID 25295646 ↗ Sep 2014 “using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU)” NCT06788587 ↗ “Lisdexamfetamine” NCT05551689 ↗ “Lisdexamfetamine” NCT00573859 ↗ |
| Known as | 608137-32-2 | “Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally” NCT05957055 ↗ |
| Known as | Elvanse | “Elvanse® (Lisdexamfetamine dimesylate capsules, hard)” NCT07098585 ↗1“Elvanse (Lisdexamfetamine): 100mg p.o, single dose” NCT02668926 ↗ |
| Known as | LDEX | “a long-acting amphetamine, lisdexamfetamine (LDEX), in patients with ADHD” PMID 35141898 ↗ Feb 2022 |
| Known as | LDX | “This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on executive function and prefrontal cortex activation in menopausal women ages 45-57,...” NCT01977625 ↗19“Objective: To examine the efficacy of lisdexamfetamine (LDX) versus placebo on behavioral attributes of sluggish cognitive tempo (SCT) in adults with...” PMID 34232582 ↗ Jun 2021 “OBJECTIVE: This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who...” PMID 26063677 ↗ Jun 2015 “This multicenter study examined lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, as adjunctive therapy to antipsychotics in adults with clinically stable...” PMID 23756608 ↗ May 2013 “This study addresses these issues - examining the extent to which clinical improvement following lisdexamfetamine (LDX) treatment is associated with changes in brain reward...” PMID 38101205 ↗ Dec 2023 “OBJECTIVE: The aim of this study was to assess the effectiveness and safety of lisdexamfetamine dimesylate (LDX) in children with attention-deficit/hyperactivity disorder (ADHD).” PMID 20035583 ↗ Dec 2009 “An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)” NCT00753012 ↗ “Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX).” NCT02555150 ↗ “Vyvanse (lisdexamfetamine; LDX) improves executive functioning (EF) in 100 postmenopausal women who report onset of EF difficulties after oophorectomy.” NCT03187353 ↗ “The proposed protocol is an open-label pilot study of the treatment of cocaine dependence using lisdexamfetamine (LDX), a prodrug of d-amphetamine.” NCT01486810 ↗ “Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD).” PMID 23708466 ↗ May 2013 “OBJECTIVE: This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions.” PMID 24796970 ↗ Jul 2014 “This study evaluated the efficacy and tolerability of lisdexamfetamine (LDX) in the treatment of bipolar depression.” PMID 25340384 ↗ Jan 2015 “Eligible participants assessed for SMD will have 4 weeks open titration with lisdexamfetamine (LDX) to optimal dose” NCT01714310 ↗ “This analysis evaluated the effect of lisdexamfetamine dimesylate (LDX) on sleep in children with ADHD.” NCT00807222 ↗ “All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol” NCT03337646 ↗ “the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant” PMID 23959815 ↗ Dec 2013 “lisdexamfetamine dimesylate (LDX) efficacy in a long-term study of adults with” PMID 21438796 ↗ Mar 2011 “Lisdexamfetamine Dimesylate (LDX)” NCT00764868 ↗ “lisdexamfetamine (LDX)” NCT03924193 ↗ |
| Known as | LDX-01 | “using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU)” NCT06788587 ↗1“treatment as usual plus lisdexamfetamine (LDX-01)” NCT05854667 ↗ |
| Known as | Lis-dexamphetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00736255 ↗ |
| Known as | Lisdexamfetamine dimesylate | “A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗21“This multicenter study examined lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, as adjunctive therapy to antipsychotics in adults with clinically stable...” PMID 23756608 ↗ May 2013 “This study tested the effect of the psychostimulant prodrug lisdexamfetamine dimesylate on amygdala activation and connectivity during the emotional bias of response execution...” PMID 29661516 ↗ Mar 2018 “Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment” NCT02635035 ↗ “Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (lisdexamfetamine dimesylate) in Children aged 6-12 Diagnosed with ADHD” NCT00500071 ↗ “Lisdexamfetamine dimesylate (LDX) was examined for ADHD participants over five weekly phases (no-drug baseline, placebo, 30-, 50-, and 70-mg LDX per day).” PMID 22166471 ↗ Dec 2011 “Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD).” PMID 23708466 ↗ May 2013 “This analysis evaluated the effect of lisdexamfetamine dimesylate (LDX) on sleep in children with ADHD.” NCT00807222 ↗ “Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet” NCT03333668 ↗ “Antidepressant + SPD489 (Lisdexamfetamine dimesylate )” NCT01436162 ↗ “Elvanse® (Lisdexamfetamine dimesylate capsules, hard)” NCT07098585 ↗ “Antidepressant + SPD489 (lisdexamfetamine dimesylate)” NCT00905424 ↗ “Vyvanse (lisdexamfetamine dimesylate), NRP104” NCT00337285 ↗ “Lisdexamfetamine Dimesylate (Medication)” NCT04599504 ↗ “Lisdexamfetamine dimesylate (Vyvanse®)” NCT03337646 ↗ “SPD489 (Lisdexamfetamine dimesylate )” NCT01436149 ↗ “lisdexamfetamine dimesylate (SPD489)” NCT01291173 ↗ “SPD489 (Lisdexamfetamine dimesylate)” NCT01718483 ↗ “SPD489 (Lisdexamfetamine dimesylate)” NCT01457339 ↗ “SPD489 (Lisdexamfetamine dimesylate)” NCT01718509 ↗ “Lisdexamfetamine Dimesylate (LDX)” NCT00764868 ↗ “Drug: Lisdexamfetamine Dimesylate” NCT00776555 ↗ |
| Known as | NRP104 | “Vyvanse (lisdexamfetamine dimesylate), NRP104” NCT00337285 ↗ |
| Known as | Racemic mixture of dextroamphetamine and lisdexamfetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00776555 ↗ |
| Known as | SPD489 | “Antidepressant + SPD489 (Lisdexamfetamine dimesylate )” NCT01436162 ↗7“Antidepressant + SPD489 (lisdexamfetamine dimesylate)” NCT00905424 ↗ “SPD489 (Lisdexamfetamine dimesylate )” NCT01436149 ↗ “SPD489 (Lisdexamfetamine dimesylate)” NCT01718483 ↗ “SPD489 (Lisdexamfetamine dimesylate)” NCT01718509 ↗ “lisdexamfetamine dimesylate (SPD489)” NCT01291173 ↗ “SPD489 (Lisdexamfetamine dimesylate)” NCT01457339 ↗ “SPD489 (lisdexamfetamine dimesylate)” NCT00922272 ↗ |
| Known as | SUB32146 | “Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally” NCT05957055 ↗ |
| Known as | Vyvanse | “A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended...” NCT00889915 ↗6“Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment” NCT02635035 ↗ “Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (lisdexamfetamine dimesylate) in Children aged 6-12 Diagnosed with ADHD” NCT00500071 ↗ “Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients” NCT03070509 ↗ “the psychostimulant, lisdexamphetamine (LDX; Vyvanse®)” NCT01986764 ↗ “Vyvanse (lisdexamfetamine dimesylate), NRP104” NCT00337285 ↗ “Lis-dexamphetamine (Vyvanse)” NCT00736255 ↗ |
| Modality | Other / unclassified | “the prodrug psychostimulant lisdexamfetamine dimesylate (LDX)” PMID 23959815 ↗ Dec 2013 |
| Route | Oral | “NRP104 capsule once-a-day orally” NCT00337285 ↗ |